Interference with CD47-SIRPα interactions has also been shown to increase ADCC by monocytes and neutrophils, making this interaction an innate immune checkpoint and an attractive target for enhancing antibody therapy in cancer (32, 33, 36). Here, CD47 is linked to cancer.